Ovarian carcinosarcoma

Search Trials
LN-145 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Status:
Recruiting
Last Changed:
Sep 10, 2019
First Changed:
Feb 28, 2018
Disease(s):
Bone Sarcoma
Intervention(s):
AldesleukinAutologous Tumor Infiltrating Lymphocytes LN-145CyclophosphamideFludarabineFludarabine PhosphateQuality-of-Life AssessmentQuestionnaire Administration
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Status:
Recruiting
Last Changed:
Sep 10, 2019
First Changed:
Aug 1, 2018
Disease(s):
High Grade Ovarian Serous Adenocarcinoma
Intervention(s):
Autologous Tumor Infiltrating Lymphocytes MDA-TILCyclophosphamideFludarabineFludarabine PhosphateInterleukin-2Quality-of-Life Assessment
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Status:
Not yet recruiting
Last Changed:
Sep 4, 2019
First Changed:
Apr 23, 2019
Disease(s):
Fallopian Tube Cancer
Intervention(s):
EntinostatOlaparib
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo

Connect. Empower. Inspire.